Healthcare provider profile · identity verified

Amy M Hernandez, MD

Family Practice · WIMBERLEY, TX · NPI 1659631901

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	447	120
Atorvastatin Calcium	Atorvastatin Calcium	352	97
Rosuvastatin Calcium	Rosuvastatin Calcium	295	90
Amlodipine Besylate	Amlodipine Besylate	254	74
Losartan Potassium	Losartan Potassium	236	69
Lisinopril	Lisinopril	208	61
Omeprazole	Omeprazole	155	54
Hydrochlorothiazide	Hydrochlorothiazide	151	48
Synthroid	Levothyroxine Sodium	136	33
Trazodone Hcl	Trazodone Hcl	131	48
Estradiol	Estradiol	112	37
Gabapentin	Gabapentin	109	44
Meloxicam	Meloxicam	108	34
Escitalopram Oxalate	Escitalopram Oxalate	99	31
Alendronate Sodium	Alendronate Sodium	98	34
Fluticasone Propionate	Fluticasone Propionate	98	35
Bupropion Xl	Bupropion Hcl	92	28
Mounjaro	Tirzepatide	87	11
Ozempic	Semaglutide	87	13
Pravastatin Sodium	Pravastatin Sodium	85	26
Simvastatin	Simvastatin	85	23
Metformin Hcl	Metformin Hcl	79	27
Alprazolam	Alprazolam	78	22
Montelukast Sodium	Montelukast Sodium	75	24
Metoprolol Succinate	Metoprolol Succinate	73	22
Zolpidem Tartrate	Zolpidem Tartrate	73	17
Metformin Hcl Er	Metformin Hcl	69	24
Pantoprazole Sodium	Pantoprazole Sodium	67	24
Sertraline Hcl	Sertraline Hcl	66	22
Fluoxetine Hcl	Fluoxetine Hcl	64	20
Tamsulosin Hcl	Tamsulosin Hcl	61	21
Duloxetine Hcl	Duloxetine Hcl	54	16
Ezetimibe	Ezetimibe	52	17
Mirtazapine	Mirtazapine	49	18
Albuterol Sulfate Hfa	Albuterol Sulfate	48	23
Valsartan	Valsartan	46	16
Azelastine Hcl	Azelastine Hcl	44	21
Carvedilol	Carvedilol	44	13
Lorazepam	Lorazepam	44	15
Valacyclovir	Valacyclovir Hcl	43	21
Tizanidine Hcl	Tizanidine Hcl	38	14
Furosemide	Furosemide	33	16
Celecoxib	Celecoxib	32	11
Citalopram Hbr	Citalopram Hydrobromide	32	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	32	13
Venlafaxine Hcl Er	Venlafaxine Hcl	32	suppressed
Armour Thyroid	Thyroid,pork	31	suppressed
Donepezil Hcl	Donepezil Hcl	31	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	31	suppressed
Eszopiclone	Eszopiclone	30	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	30	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	29	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	28	11
Jardiance	Empagliflozin	28	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	27	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	26	suppressed
Paroxetine Hcl	Paroxetine Hcl	26	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	26	suppressed
Diazepam	Diazepam	22	suppressed
Glimepiride	Glimepiride	22	suppressed
Progesterone	Progesterone, Micronized	22	suppressed
Spironolactone	Spironolactone	22	suppressed
Fenofibrate	Fenofibrate	21	suppressed
Methocarbamol	Methocarbamol	21	suppressed
Pregabalin	Pregabalin	21	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	21	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	20	suppressed
Ventolin Hfa	Albuterol Sulfate	20	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	19	18
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	19	suppressed
Clonazepam	Clonazepam	19	suppressed
Doxepin Hcl	Doxepin Hcl	19	suppressed
Famotidine	Famotidine	19	suppressed
Telmisartan	Telmisartan	19	suppressed
Buspirone Hcl	Buspirone Hcl	18	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	18	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	18	suppressed
Enalapril Maleate	Enalapril Maleate	18	suppressed
Finasteride	Finasteride	18	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	18	suppressed
Ropinirole Hcl	Ropinirole Hcl	18	suppressed
Tramadol Hcl	Tramadol Hcl	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	14
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	18	suppressed
Allopurinol	Allopurinol	17	suppressed
Invokana	Canagliflozin	17	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	17	suppressed
Potassium Chloride	Potassium Chloride	17	suppressed
Solifenacin Succinate	Solifenacin Succinate	17	suppressed
Topiramate	Topiramate	17	suppressed
Trulicity	Dulaglutide	17	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	16	suppressed
Atenolol	Atenolol	16	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	16	suppressed
Testosterone	Testosterone	16	suppressed
Prednisone	Prednisone	15	11
Clobetasol Propionate	Clobetasol Propionate	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Lamotrigine	Lamotrigine	14	suppressed
Lovastatin	Lovastatin	14	suppressed
Myrbetriq	Mirabegron	14	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	13	suppressed
Cephalexin	Cephalexin	13	12
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Ibandronate Sodium	Ibandronate Sodium	13	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	12	12
Methylphenidate Hcl	Methylphenidate Hcl	12	suppressed
Promethazine Hcl	Promethazine Hcl	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	11	suppressed
Lactulose	Lactulose	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error